Forbion Capital Partners invests in Curetis

Roche Venture Fund, CD-Venture and the management joined Forbion in the round.

The deal marks the first investment of Forbion in Curetis, made from its Forbion Capital Partners II fund. Forbion has been observing the medical diagnostics firm since 2009 and decided to invest now when the opportunity emerged to participate in the series-A round backed by several venture capital houses.

The investor believes there is demand in the market for faster identification of pathogens and resistance markers due to increasing antibiotic and multidrug resistance.

Curetis has finalised the preclinical testing and is looking to launch clinical trials. The business plans a European market launch of the platform and pneumonia application in 2012.

Company
Curetis is based in Holzgerlingen and was founded in 2007. The company is a molecular diagnostics company focusing on the development and commercialisation of in-vitro products for the diagnosis of severe infectious diseases.

Curetis has developed the Unyvero instrument platform to detect multi-parameter pathogen and antibiotic resistance within a few hours instead of several days.

Currently the firm employs 21 people and has recently opened a large manufacturing floor site in Bodelshausen, Germany.

People
Holger Reithinger is partner at Forbion and has joined Curetis's board of directors.

Advisers
Equity – CMS Hasche Sigle, Stefan-Ulrich Müller, Sebastian Wilhelm (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Germany